QRG Capital Management Inc. Trims Stock Position in Hologic, Inc. (NASDAQ:HOLX)

QRG Capital Management Inc. lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 86,967 shares of the medical equipment provider’s stock after selling 5,509 shares during the quarter. QRG Capital Management Inc.’s holdings in Hologic were worth $6,269,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. General Partner Inc. acquired a new stake in shares of Hologic during the 4th quarter worth approximately $26,000. Groupama Asset Managment grew its position in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC increased its holdings in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares in the last quarter. Finally, Covestor Ltd raised its position in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.3 %

NASDAQ HOLX opened at $63.38 on Friday. The firm has a market capitalization of $14.22 billion, a price-to-earnings ratio of 19.99, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a one year low of $62.69 and a one year high of $84.67. The company’s 50 day moving average price is $69.16 and its 200 day moving average price is $75.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on HOLX shares. Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research note on Monday, February 3rd. UBS Group lifted their price target on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Raymond James reaffirmed an “outperform” rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.